Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

已完结 10 由达姆发布于 2026/3/24 16:18:03

DOI:10.1016/s2468-1253(25)00268-7
作者：Zheng Wang, Lixing Li, Peiran Huang, Honghu Tu, Xiangyu Zhang, Lei Yu, Fei Liang, Cheng Huang, Shuangjian Qiu, Qinghai Ye, Zhenbin Ding, Xiaowu Huang, Yinghong Shi, Kang Song, Huichuan Sun, Xiaoying W
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundPatients with intrahepatic cholangiocarcinoma have a poor prognosis and high postoperative recurrence rates. Immunochemotherapy has been approved as a first-line treatment for adva

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierReactive molecular dynamics simulation of the mechanical behavior of sodium aluminosilicate geopolymer and calcium silicate hydrate composites